Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abiding no more

Venture infusion takes Apexigen off shoe-string budget for rabbit-derived mAbs

Abiding no more

Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus partnership

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers